SEOUL, October 02 (AJP) - SK Life Science, the U.S. subsidiary of South Korea’s SK Biopharm, reported record sales of its epilepsy treatment cenobamate in the first half of this year, reaching 170,000 cumulative prescriptions.
The company highlighted the achievement during its annual “Plan of Action” meeting in Chicago, as it looks to build momentum in one of the world’s most competitive pharmaceutical markets.
More than 130 employees from SK Life Science and SK Biopharm gathered from Sept. 29 to Oct. 1 to review performance and outline next steps. Executives said the results marked the strongest sales since Xcopri, as the drug is marketed in the United States, was introduced in 2020.
The Chicago meeting, now in its sixth year, also brought in senior staff from the Seoul headquarters to reinforce collaboration between the U.S. unit and its parent company. The event was designed not only to showcase achievements but also to motivate employees ahead of the next growth phase.
SK Biopharm, which became the first South Korean drugmaker to build a direct sales operation in the United States, plans to leverage cenobamate’s success to expand its portfolio.
“SK Biopharm stands at a crucial turning point to diversify our portfolio and target both current and future markets,” said Lee Dong-hoon, the company’s chief executive. “We expect all divisions to collaborate as one team to create greater synergy.”
* This article, published by Aju Business Daily, was translated by AI and edited by AJP.
Copyright ⓒ Aju Press All rights reserved.
